SAB Biotherapeutics (SABS) Stock Chart & Stock Price History $1.74 -0.10 (-5.30%) As of 02:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics Stock Price Performance The SAB Biotherapeutics (SABS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 40.03%, with a year-to-date return of -53.96%. In the past month, the stock has increased 22.38%, reflecting recent market activity. As of the latest close, SAB Biotherapeutics traded at $1.84 with a market cap of $17.12 million and volume of 17,537 shares. Receive SABS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-5.68%1 Month Performance+22.38%3 Month Performance-4.12%Year-To-Date Performance-53.96%1 Year Performance-40.03% SABS Stock Chart for Wednesday, May, 21, 2025 SABS Chart by TradingView SAB Biotherapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/20/2025$1.80$1.84+2.37%$1.86$1.8017,537 shs$17.12 million05/19/2025$1.85$1.80-2.70%$1.93$1.7735,496 shs$16.73 million05/16/2025$1.94$1.85-4.64%$2.10$1.8428,466 shs$17.19 million05/15/2025$1.85$1.94+4.86%$2.10$1.83320,772 shs$18.02 million05/14/2025$1.88$1.85-1.44%$2.03$1.7647,012 shs$17.19 million05/13/2025$1.98$1.88-5.20%$2.01$1.8623,178 shs$17.44 million05/12/2025$1.79$1.98+10.61%$2.15$1.78143,573 shs$18.39 million05/09/2025$1.73$1.79+3.53%$1.80$1.6716,972 shs$16.63 million05/08/2025$1.69$1.73+2.30%$1.85$1.726,629 shs$16.06 million05/07/2025$1.60$1.69+5.63%$1.80$1.6857,765 shs$15.70 million Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/06/2025$1.70$1.60-5.88%$1.87$1.61141,317 shs$14.86 million05/05/2025$1.60$1.70+6.25%$1.79$1.59114,373 shs$15.79 million05/02/2025$1.71$1.60-6.49%$1.66$1.5346,928 shs$14.86 million05/01/2025$1.70$1.71+0.65%$1.70$1.649,112 shs$15.89 million04/30/2025$1.66$1.70+2.72%$1.78$1.5817,633 shs$15.79 million04/29/2025$1.77$1.66-6.23%$1.78$1.6411,598 shs$15.37 million04/28/2025$1.75$1.77+0.86%$1.81$1.6432,743 shs$16.40 million04/25/2025$1.50$1.75+16.67%$1.75$1.4443,951 shs$16.26 million04/24/2025$1.37$1.50+9.49%$1.50$1.348,093 shs$13.93 million04/23/2025$1.30$1.37+5.38%$1.40$1.3015,427 shs$12.73 million04/22/2025$1.43$1.30-8.83%$1.45$1.3037,066 shs$12.08 million04/21/2025$1.43$1.43-0.56%$1.49$1.3353,700 shs$13.25 million Related Companies FBIO Stock Chart CRIS Stock Chart BOLT Stock Chart MTEM Stock Chart AMGN Stock Chart GILD Stock Chart VRTX Stock Chart REGN Stock Chart ALNY Stock Chart BIIB Stock Chart Receive SABS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SABS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
